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The renin-angiotensin system (RAS) is well known as regulator of electrolytes and blood
pressure. Besides this function, there are numerous studies supporting the idea of a local
tissue RAS. This system controls the local activity of the different RAS family members,
especially of the functional proteins Angiotensin II and Angiotensin (1–7). Those antago-
nistically acting proteins have been described to be expressed in different organ systems
including the human reproductive tract. Therefore, this local RAS has been suspected to
be involved in the control and regulation of physiological and pathological conditions in the
female reproduction tract.This review of the available literature summarizes the physiologi-
cal influence of the RAS on the follicular development, ovarian angiogenesis, and placental-
and uterine function. In addition, in the second part the role of the RAS concerning ovarian-
and endometrial cancer becomes elucidated. This section includes possible novel thera-
peutic strategies via inhibition of RAS-mediated tumor growth and angiogenesis. Looking
at a very complex system of agonistic and antagonistic tissue factors, it may be supposed
that the RAS in the female reproduction tract will be of rising scientific interest in the
upcoming years.
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INTRODUCTION
The Renin-Angiotensin system (RAS) is of paramount impor-
tance for the perpetuation of the circular flow, regulating the
electrolyte metabolism thus the blood pressure (1–4). This con-
siderable function of the RAS is mediated by the systemic RAS-
pathway. The latter consists of a cascade of peptides, acting as
precursors which become transformed by different enzymes into
the bioactive end products (5). The main protein of this sys-
tem is Angiotensinogen, which is synthesized in the liver (6).
Following the pathway, Angiotensinogen becomes converted into
Angiotensin I, catalyzed by Renin, which is of renal origin.
Subsequently, Angiotensin I can be further modulated by the
angiotensin-converting enzyme (ACE) I to Angiotensin II or by
ACE II to Angiotensin (1–9).
Angiotensin (1–9) then becomes transformed by ACE or neu-
tral endopeptidase (NEP) into Angiotensin (1–7) (7–9). Those
two bioactive effector molecules, Angiotensin II and Angiotensin
(1–7) act in an antagonistic way by binding to different receptors:
angiotensin receptor type 1 (AT1R) and type 2 (AT2R) or Mas-
receptor (10). The G-coupled Mas-receptor mediates vasodilatory
and anti-proliferative effects and antagonizes actions of the AT1R
(11). In recent years, attention has also focused on the evidence of
a widespread local tissue RAS (12). Expression of elements of this
local RAS has been described in different parts of the human repro-
ductive tract. Apparently, the both antagonistic bioactive proteins
of the RAS, in particular Angiotensin II and Angiotensin (1–7)
can result from the local tissue RAS (13, 14). This local produc-
tion of the bioactive peptides is not necessarily dependent on
the local expression of all components of the local tissue RAS,
since it is also possible to take up components from the circula-
tion, such as renin. Furthermore, besides presence of Angiotensin
II and Angiotensin (1–7), expression of AT1R, AT2R, and Mas-
receptor human reproductive tissue is needed in order to mediate
the local impact of the RAS for physiological and pathologi-
cal processes, including follicle maturation, fine-tuning of the
regulation of reproduction, angiogenesis as well as tumor cell
proliferation (15–18). An influencing effect on cancer has been
described for different tumor types already during the last two
decades (19, 20).
MATERIALS AND METHODS
We performed a systematic literature review concerning pres-
ence and function of the RAS in the female reproduction tract.
This was based on the medical databases Medline, Embase, BIO-
SIS, and CINHAL. Literature analysis was conducted without a
timeframe on all existing publications including 2013. All man-
uscripts were sighted based on the title and abstract and any
duplicate manuscripts occurring in the literature search were
excluded. After fulfilling the inclusion criteria (content-related,
experimental, and clinical studies, in the case of experimen-
tal studies dividing into studies in humans and/or animals) the
manuscripts were reviewed and analyzed. Thereby, the data was
extracted and content-related articles allocated into two different
groups:
• Physiological role of the RAS in the reproductive tract?
• Role of the RAS in gynecologic cancers.
www.frontiersin.org October 2013 | Volume 4 | Article 150 | 1
Herr et al. RAS in reproduction
PHYSIOLOGICAL ROLE OF THE RAS IN THE REPRODUCTIVE
TRACT
OVARY AND FOLLICULAR DEVELOPMENT
Definitely, a local tissue RAS is present in the adult ovary (18). In
the human ovary, all family members of the RAS have been proven
at the protein level, whereas in the bovine, porcine, and rat ovary
only single compounds of the RAS are expressed (12, 21–23). It has
been speculated, that the attendance of RAS compounds is signif-
icantly involved in the regulation of fetal development since RAS
expression can be observed in the porcine ovary already around
45 days of gestation: AT1R and AT2R have been detected in gran-
ulosa cells of primordial, primary, and secondary follicles (23).
In addition, Angiotensin II and its receptors AT1R/AT2R seem
to have regulatory effects in the ovary regarding oocyte nuclear
maturation and ovulation (24–27). This regulative function has
mainly been investigated in antral follicles, but also in porcine
granulosa cells of earlier stages of follicular development (28).
Obviously, there are significant differences between the species.
When bovine Cumulus oocyte complexes (COCs) were culti-
vated with Angiotensin II, nuclear maturation of the oocyte was
induced (12, 26). Furthermore, Ferreira et al. indicated that Ang
II may have an impact on bovine ovulation via AT2R (25). In
addition, functional studies have demonstrated that inhibition of
the AT2R prevents bovine ovulation significantly (29). In rats,
AT1R is expressed in healthy follicles (30) and AT2R-expression is
obviously involved in follicular atresia through apoptosis (31, 32).
Unfortunately, the published data concerning involvement of
the RAS in the regulation of the hormonal regulation of the ovary
is scanty and sometimes inconsistent. For example, for the bovine
corpus luteum, it has been shown, that tissue levels of Angiotensin
II do not change throughout the cycle, indicating that steroids may
have no influence on tissue RAS (33). In conflict with this finding, a
significant influence of the RAS on progesterone synthesis has been
described (34, 35). The observed increase of progesterone and sol-
uble and membrane-bound aminopeptidase A was accompanied
by a decrease of membrane-bound aminopeptidases B/N (RAS-
regulating enzymes) due to inhibition alpha 1-adrenergic recep-
tors in rats (35). In addition, the data concerning gonadotropin-
dependent expression of RAS-proteins is disputed: it has been
shown that application of hCG in case of early pregnancy has
the capacity to activate the local RAS in the ovary (36), whereas
our own group observed a significant hCG-dependent decrease of
Angiotensin II in human granulosa lutein cells in vitro (37). This
result goes in line with the perception that the antagonistically to
Angiotensin II acting Angiotensin (1–7) and its receptor Mas were
found to be increased after gonadotropin stimulation in the rat
ovary (22). Basically, the role of Angiotensin (1–7) seems to be of
increasing interest: Angiotensin (1–7), Mas-receptor, and ACE 2
were identified in all stages of follicular development in humans
(38) and functional studies indicate a role of the Angiotensin (1–
7)-pathway in the rodent in vivo (39) suggesting to be a mediator
of gonadotropin functions in the ovulatory cascade (40).
OVARIAN VASCULATURE FUNCTION AND ANGIOGENESIS
The most outstanding data in the literature has been published
concerning the regulatory character of the RAS on vascular func-
tion and angiogenesis in the ovary. The invoking effects on the
vessels are thereby first of all adapted from the Angiotensin II-
AT1R-pathway (41–44). To be contrary to this, the restitution
of the luteal vasculature is mediated by the AT2R-pathway (45).
Anyway, Angiotensin II obviously influences the microvascular
endothelial function in the corpus luteum (42). Hayashi et al.
demonstrated that microvascular endothelial cells (MVE) in the
corpus luteum express ACE and are capable to convert Angiotensin
I into Angiotensin II. The Angiotensin II production thereby
increases significantly under stimulation with estradiol in com-
bination with vascular endothelial growth factor (VEGF) (41).
MVE furthermore possess AT1R and AT2R (41, 42). Interest-
ingly, the expression of those two receptors differ throughout
the cycle: AT1R remains constant but AT2R-expression is low-
est during the mid luteal phase and highest during the late luteal
phase (41, 46). The regulation of angiogenic processes is urgently
needed to ensure the constant flow of growth, maturation, and
demise of the corpus luteum. It has been shown by our group,
human granulosa lutein cells collected during in vitro fertilization
(IVF) are expressing several components of the RAS (47). In addi-
tion, we demonstrated that exogenous Angiotensin II stimulation
increased VEGF synthesis via AT1R signaling in vitro (47). This
data may implicate the regulatory effect of the RAS on angiogene-
sis in the corpus luteum. In agreement with its meaning concerning
control of systemic blood pressure, the individual family members
of the local RAS also regulate perfusion and vascular tone in the
ovary (36, 44).
PLACENTA
The human placenta is one of the most interesting tissues in the
reproductive tract, because the utero-placental unit provides a
transposition of nutritive substances and oxygen between mother
and fetus. It has been assumed by many authors that the RAS
influences the placental function (48–52), since all different com-
ponents of the RAS are expressed in human placenta cell lines
(53) as well in placental tissue (54, 55). However, functional
data of the placental RAS is very rare. Obviously, the different
RAS-proteins are expressed differentially in the various areas of
this organ: angiotensinogen, Renin, Angiotensin I, Angiotensin
II, ACE, AT1R, and AT2R were localized to maternal decidua
(56, 57) and Angiotensin II and ACE were additionally found in
pericytes of endometrial spiral arteries. However, Angiotensino-
gen and renin also have been detected in fetal capillaries (58).
The AT1R, which is predominantly expressed in the placenta, was
found in cytotrophoblast and syncytiotrophoblast cells as well as
in fetal capillaries, while little is known concerning localization
of the AT2R (59, 60). The antagonistic proteins to Angiotensin II,
namely Angiotensin (1–7) and ACE2 were found to be expressed in
syncytiotrophoblast, cytotrophoblast, and vascular smooth mus-
cle cells of primary and secondary villi (58). The above mentioned
members of the RAS family can be detected from 6 weeks of gesta-
tion until birth. Obviously, there are some variations in the course
of pregnancy: it has been shown that mRNA of ACE is increas-
ing during gestation but decreases near term. In addition, AT1R
mRNA and AT1R protein levels are rising throughout the entire
pregnancy, reaching highest levels at the end (61). Since a direct
connection between Angiotensin II and AT1R has been observed
in the placenta, it has been supposed that this fact indicates a
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regulating effect of Angiotensin II on the AT1R expression (62).
From a more clinical point of view, there are several references
that the placental RAS is involved in trophoblast invasion and
angiogenesis (63, 64), being a possible cause of defect for the devel-
opment of conditions with disordered utero-placental perfusion,
namely preeclampsia (see below).
FALLOPIAN TUBE
Data concerning the RAS and the oviduct is rare. Any clinical
relevant findings have not been published. However, Angiotensin
II has been localized in blood vessel endothelium and in stromal
cells. Both binding and Angiotensin II type-2 receptor mRNA were
detected at high levels, but no differences in receptor concentra-
tion could be detected in fallopian tubes ipsilateral or contralateral
to the corpus luteum (65).
UTERUS
Outline above, the data of uterine RAS are of descriptive nature
and mostly limited to the endometrium. Studies investigating the
functional relevance of the RAS in the uterus are rare.
Being an indispensible part of the reproductive tract, the
endometrium underlies a cyclic change of growth and degrada-
tion. Basically, all elements of the local tissue RAS are expressed in
the endometrium (66), however this expression diversifies during
the cycle (46, 67): angiotensin II underlies cyclic variances within
the endometrium and is increased during the proliferative phase,
and decreased during the secretory phase (68). Angiotensin-(1–7)
and its receptor MAS is also present throughout the menstrual
cycle but increases in the glandular endometrium in the mid and
late secretory phase. Although AT1R and AT2R are expressed in the
endometrium, expression of AT2R is more frequent and varying
(68) and it is down-regulated during pregnancy (69). The AT2R-
expression is thereby most prominent in the myometrium (up to
90%) as compared to AT1R expression (up to 10%). Unfortunately,
data concerning functional effects of the RAS in the uterus is rare.
Since endometrium is controlled by female sex hormones, it has
been supposed that the RAS might also be influenced by those hor-
mones. This assumption is supported by the finding, that the local
expression and production of renin is increased after stimulation
with progesterone (70).
PATHOPHYSIOLOGICAL ROLE OF THE RAS IN THE
REPRODUCTIVE TRACT
During the past few years, the primary small number of pub-
lications concerning pathophysiologic aspects of the RAS has
been markedly increased. This affects aspects of reproduction, in
essence preeclampsia, as well as of the role of the RAS controlling
gynecological cancers. Thereby, the most resilient data is avail-
able regarding the regulatory aspects on tumor cell proliferation,
vascular function, and angiogenesis (71).
RAS AND REPRODUCTION
In patients with polycystic ovary syndrome, the intra-follicular
renin, which is needed for synthesis of the bioactive peptides of the
RAS, affects maturation and oocyte quality (43). Follicles with high
levels of renin indicating a high local RAS activity, were associated
with better oocyte quality and showed higher VEGF concentra-
tions during IVF procedures (43). Furthermore,a strong activation
of the local ovarian RAS by beta-hCG has been observed during
IVF treatment. This process was also associated with an increased
VEGF concentration. Consequently, it has been assumed, that
the activation of the ovarian RAS and consecutive high levels of
VEGF might act synergistically during pathogenesis of ovarian
hyperstimulation syndrome (OHSS).
Although the role of the RAS concerning invasion of tro-
phoblast and placentation is poorly investigated, there is evi-
dence that dysfunction of this system may cause hypertension and
preeclampsia (56, 72, 73, 74): patients with preeclampsia present
with increased expression of Angiotensin II and AT1R in maternal
decidua cells and in the placenta itself (74, 75). In pre-eclamptic
pregnancies Angiotensin II and AT1R was been observed to be
increased, whereas levels of Angiotensin I,Angiotensin (1–7),ACE,
and ACE2 were normal as compared to healthy pregnancies (48).
Current data describe a relevant clinical link between RAS and
preeclampsia: women with a male fetus who developed gestational
hypertension had increased Angiotensin (1–7) levels at 15 weeks
gestation compared with women with normal pregnancies, sug-
gesting that these women were on an early trajectory for the
development of hypertension. Therefore, the authors proposed
measurement of Ang-(1–7) during early pregnancy in order to
predict new-onset hypertension (76).
In addition Valdes et al. also reported elevated Angiotensin
(1–7) concentrations in spontaneously aborted and ectopic early
pregnancy placentas, which lead the authors to hypothesize that
the ACE2–Angiotensin-(1–7) axis plays a functional role in placen-
tal development (77). Further recent data underlines the connec-
tion between RAS and preeclampsia, since there is an association
with a polymorphism of Angiotensinogen in Chinese women. This
finding might cause disordered vasculogenesis contributing to the
development of preeclampsia (78).
OVARIAN CANCER
The published data apropos RAS and invasive epithelial ovarian
cancer provides a role concerning proliferation and dissemina-
tion of cancer cells and tumor-angiogenesis. Ovarian cancer cells
express Angiotensin II and AT1R (79) but there is still missing
evidence of the other components of the local RAS in ovarian
cancer. It has been shown that levels of AT1R are higher in border-
line lesions and in invasive epithelial ovarian cancer as compared
with normal ovaries (80). Being in line with this finding, ovar-
ian cancer patients presenting with high levels of AT1R, have a
worse prognosis in comparison with tumors lacking the AT1R
expression. Obviously, the Angiotensin II→AT1R pathway is able
to influence ovarian cancer cell proliferation (80). Since it has
been shown that levels of VEGF as well as rates of angiogen-
esis are increased due to Angiotensin II, the link between the
RAS and Angiogenesis has been established in epithelial ovarian
cancer cells (80). At least in vivo, this connection even acts quan-
titatively: stimulation of the ovarian cancer cell line Scov 3 with
Angiotensin II caused increased VEGF expression (80) and high
levels of AT1R are associated with significantly increased VEGF
production and micro-vessel density (MVD) (79). All those find-
ings might indicate a therapeutical approach. Therefore, inhibition
of AT1R has been performed in mice with peritoneal carcino-
matosis, leading to a significant decrease of ascites and peritoneal
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tumor cell dissemination. In patients, current data at least indicate
that agonistic auto antibodies against AT1R may be associated
with advanced progression of early ovarian cancer (81). These
findings implicate that AT1-AA might be selected as a detectable
biomarker and potential therapeutic target in diagnosis and treat-
ment of EOC patients. Summing up, it appears that two substantial
mechanisms, increased tumor cell proliferation and angiogenesis
are mediated by the RAS. Therefore, targeting the Angiotensin
II→AT1R pathway could provide a future treatment strategy for
invasive epithelial ovarian cancer.
ENDOMETRIAL CANCER
Similarly to ovarian cancer, there are proofs for a possible influ-
ence of the local RAS concerning endometrial cancer. It has been
published that in endometrial cancer, prognosis, tumor cell pro-
liferation, and angiogenesis are affected by the RAS (82). Accord-
ing to the situation in the ovary, again increased local levels of
Angiotensin II are associated with poorer prognosis in endome-
trial cancer patients (82, 83). This finding might be due to the fact,
that those higher levels of Angiotensin II were found in patients
with an advanced tumor stage (82). In this study, 81.9% were posi-
tive for Ang II and 59.6% positive for the AT1R. However, it seems
as not only progression of disease but also an increased risk for
developing endometrial cancer might be mediated by the RAS: a
polymorphism of ACE has been described to be associated earlier
onset of this disease (84). Again, the Angiotensin II→AT1R axis
increases VEGF and thereby angiogenesis in a dose-dependent way
(83). Recently, it has even speculated that Angiotensin II modulates
the VEGF type-2 receptor KDR via AT1R (85). Inversely regarded,
the connection of the RAS with angiogenesis is supported by
the fact that low Angiotensin II activity is associated with less
VEGF and a decreased MVD. This relation was basis for functional
experiments: the treatment with the AT1R-blocker Losartan has a
anti-proliferative effect in endometrial cancer tissue in vitro (86).
In summary, high activity of the local RAS in endometrial cancer
is associated with higher incidences, earlier onset, and increased
rates of angiogenesis. The roles of Ang-(1–7) and the AT2R as well
as clinical randomized study data is completely lacking and need
to be further investigated.
CONCLUSION
This review summarizes the available literature concerning the
local tissue RAS in the reproductive tract with regards to physi-
ological and pathological clinical situations. The majority of the
published studies remain on a non-functional descriptive level,
but nevertheless, a role of the local tissue RAS as regulator in
the human reproductive tract van be supposed. Obviously, the
RAS affects oocyte maturation and quality, endometrial lining
as well as hormone production and may therefore be consid-
ered as important system for regulation of physiologic pathways.
Furthermore, the published data indicates a potential involve-
ment of the local RAS in affecting physiological angiogenesis in
the reproductive tract. Currently, pathologic conditions are better
investigated than physiology. The Angiotensin II→AT1R path-
way promotes tumor growth and angiogenesis in malignancies,
arising new treatment strategies by inhibition of the AT1R. Data
concerning stimulation of the antagonistic pathways such as the
AT2R or Angiotensin (1–7) pathway as treatment modality for
ovarian- or endometrial cancer is lacking. Due to current data,
it is clear that most conclusions made are speculative since only
a negligible number of functional studies have been conducted
and clinical randomized data is missing completely. However,
regarding a very complex and variable system of agonistic and
antagonistic tissue factors, it may be hypothesized that the RAS in
the female reproduction tract will be of increasing interest in the
near future.
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